Revolution Medicine has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial ...

For more than two decades, oncologists treating advanced pancreatic cancer have watched new drugs fail to move the survival ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...

Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.

Investigators compared cancer-specific survival rates after synchronous vs metachronous metastasis in patients with surgically treated renal cell carcinoma (RCC).

For the roughly 64,000 Americans diagnosed with pancreatic cancer each year, the prognosis remains grim — though regimens ...

The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic ...

Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib ...

For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and ...

During a live event, Mark Yarchoan, MD and participants weighed new phase 3 immunotherapy combos for unresectable HCC, ...

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, ...

Updated findings from the phase 3 ROSELLA trial (NCT05257408) showed that combining relacorilant (Lifyorli) with ...